Evidence map›Paper›PMID 31970214›Full record

ArticleMovement disorders clinical practice2020

Hyperphosphorylated Tau, Increased Adenylate Cyclase 5 (ADCY5) Immunoreactivity, but No Neuronal Loss in ADCY5-Dyskinesia.

Dong-Hui Chen, Caitlin S Latimer, Min Spencer, Prasanthi Karna, Luis F Gonzalez-Cuyar, Marie Y Davis, C Dirk Keene, Thomas D Bird, Wendy H Raskind

Open access · bronzeAbstract read
In one paragraph

Article in Movement disorders clinical practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Scoping Review on ADCY5-Related Movement Disorders.Movement disorders clinical practice · 2023
    Article
  4. Identification of SNPs inFrontiers in genetics · 2023
    Article
  5. Classification of diseases with accumulation of Tau protein.Neuropathology and applied neurobiology · 2022
    Article
  6. Some New and Unexpected Tauopathies in Movement Disorders.Movement disorders clinical practice · 2020
    Article
  7. Novel advanced patient-derivedFrontiers in neurology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dong-Hui ChenDepartment of Neurology University of Washington Seattle Washington USA.
Caitlin S LatimerDepartment of Pathology, Neuropathology Division University of Washington Seattle Washington USA.
Min SpencerDepartment of Medicine, Division of Medical Genetics University of Washington Seattle Washington USA.
Prasanthi KarnaDepartment of Medicine, Division of Medical Genetics University of Washington Seattle Washington USA.
Luis F Gonzalez-CuyarDepartment of Pathology, Neuropathology Division University of Washington Seattle Washington USA.
Marie Y DavisDepartment of Neurology University of Washington Seattle Washington USA.
C Dirk KeeneDepartment of Pathology, Neuropathology Division University of Washington Seattle Washington USA.
Thomas D BirdDepartment of Neurology University of Washington Seattle Washington USA.
Wendy H RaskindDepartment of Medicine, Division of Medical Genetics University of Washington Seattle Washington USA.
University of Washington · USUniversity of Washington Medical Center · USMental Illness Research, Education and Clinical Centers · US

Funding

THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
CSRD VA I01 CX001702NIA NIH HHS P50 AG005136
6 · The paper itself

Abstract

backgroundAdenylate cyclase 5 (ADCY5)-related dyskinesia is a childhood-onset movement disorder. Manifestations vary in frequency and severity and may include chorea, tremor, dystonia, facial twitches, myoclonus, axial hypotonia, and limb hypertonia. Psychosis is likely part of the broader spectrum. ADCY5 is widely expressed in the brain, especially in the striatum. Previous reports of brain autopsies of 2 subjects with likely ADCY5-dyskinesia were limited by the absence of a molecular diagnosis. In 1 case, normal gross pathology was reported. In the other case, ADCY5 expression was not examined and neuropathological findings were confounded by age and comorbidities.

objectivesTo examine ADCY5 expression and neuropathological changes in ADCY5-dyskinesia.

methodsAn extensive brain autopsy, including immunohistochemical analyses with antibodies to paired helical filament tau, α-synuclein, amyloid-β, microtubule-associated protein 2, and ADCY5, was performed.

resultsThe patient, with a p.M1029K ADCY5 variant, had severe dyskinesias from early childhood, later recurrent episodes of psychosis, and died at age 46. Gross pathology was unremarkable, but we detected increased immunoreactivity for ADCY5 in neurons in multiple brain regions. Despite no history of brain trauma to suggest chronic traumatic encephalopathy, we found tau deposits in the deep cortical sulci, midbrain, and hippocampus with minimal amyloid pathology and no Lewy bodies.

conclusionsWe present the first brain autopsy findings in a molecularly proven case of ADCY5-dyskinesia, showing increased ADCY5 immunoreactivity in neurons and evidence of tau deposition. Additional patients will need to be studied to determine whether increased immunoreactivity for ADCY5 is a signature for ADCY5-dyskinesia and whether this disease has a tauopathy component.

Indexed as

ADCY5‐dyskinesianeurogeneticsneuropathologytau

Identifiers

PMID31970214
PMCPMC6962666
OpenAlexW2991127827

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.